JFJean-Claude Florent

Jean-Claude Florent

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Claude Florent has a total of 240 co-authors. Here are the top co-authors by number of shared publications:

  • Claude Monneret

    UMR 176 CNRS/Institut Curie, Centre de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France

    20 shared publications
  • Claude Monneret

    Institut Curie Recherche, Pavillon Trouillet‐Rossignol, CNRS UMR 176, 26 Rue d'Ulm, 75231 Paris cedex 05, France

    10 shared publications
  • Frédéric Schmidt

    Cellular and Chemical Biology Unit, U1143 INSERM, UMR3666 CNRS, Institut Curie— Université PSL 26 rue d'Ulm 75248 Paris Cedex 05 France

    10 shared publications
  • Ludger Johannes

    Chemical Biology of Cancer Unit, Institut Curie, U1339 INSERM, UMR3666 CNRS, PSL Research University, Paris, France

    10 shared publications
  • Caroline Barette

    Institut de Recherche Interdisciplinaire de Grenoble, Laboratoire Bioscience et bioinGénierie pour la santE, Commissariat à l'Energie Atomique, INSERM, Université Grenoble Alpes, Grenoble, France

    6 shared publications
  • Emmanuel Bertounesque

    Contribution from the Department of Chemistry, the Laboratory for Research on the Structure of Matter, and the Monell Chemical Senses Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104

    6 shared publications

Latest Publications

  • Open Access

    Mechanism of Shiga Toxin Clustering on Membranes

    by Weria Pezeshkian, Haifei Gao, Senthil Arumugam, Ulrike Becken, Patricia Bassereau, Jean-Claude Florent, John Hjort Ipsen, Ludger Johannes, Julian C. Shillcock

    The bacterial Shiga toxin interacts with its cellular receptor, the glycosphingolipid globotriaosylceramide (Gb3 or CD77), as a first step to entering target cells. Previous studies have shown that toxin molecules cluster on the plasma membrane, despite the apparent lack of direct interactions between them. The precise mechanism by which this clustering occurs remains poorly defined. Here, we used vesicle and cell systems and computer simulations to show that line tension due to curvature, height, or compositional mismatch, and lipid or solvent depletion cannot drive the clustering of Shiga toxin molecules. By contrast, in coarse-grained computer simulations, a correlation was found between clustering and toxin nanoparticle-driven suppression of membrane fluctuations, and experimentally we observed that clustering required the toxin molecules to be tightly bound to the membrane surface. The most likely interpretation of these findings is that a membrane fluctuation-induced force generates an effective attraction between toxin molecules. Such force would be of similar strength to the electrostatic force at separations around 1 nm, remain strong at distances up to the size of toxin molecules (several nanometers), and persist even beyond. This force is predicted to operate between manufactured nanoparticles providing they are sufficiently rigid and tightly bound to the plasma membrane, thereby suggesting a route for the targeting of nanoparticles to cells for biomedical applications.


  • Metal‐Free Activation of a C(sp)−H Bond of Aryl Acetylenes

    by Laxmidhar Rout, Bibhuti Bhusan Parida, Jean‐Claude Florent, Ludger Johannes, Santosh Kumar Choudhury, Ganngam Phaomei, Joe Scanlon, Emmanuel Bertounesque

    C(sp)−H Bond activation of acetylene molecule still remains a challenge for synthetic organic chemists. In practice, acetylenes are activated by strong bases and metals. The first example for activating acetylenic protons under base and metal‐free conditions is reported here. It involves a general method for synthesizing propargylic derivatives of cotarnine. An array of tetrahydroisoquinolines alkaloids was synthesized by C(sp)−H bond activation of aromatic acetylenes with cotarnine at room temperature. A DFT‐based mechanism is proposed for the reaction.


  • Targeted Shiga toxin–drug conjugates prepared via Cu-free click chemistry

    by Vesela Kostova, Estelle Dransart, Michel Azoulay, Laura Brulle, Siau-Kun Bai, Jean-Claude Florent, Ludger Johannes, Frédéric Schmidt


  • Carbohydrate Conformation and Lipid Condensation in Monolayers Containing Glycosphingolipid Gb3: Influence of Acyl Chain Structure

    by Erik B. Watkins, Haifei Gao, Andrew J.C. Dennison, Nathalie Chopin, Bernd Struth, Thomas Arnold, Jean-Claude Florent, Ludger Johannes


  • Chimiothèque de petites molécules, outil de recherche pour la biologie chimique

    by Jean-Claude Florent

    Obtaining and screening collections of small molecules remain a challenge for biologists. Recent advances in analytical techniques and instrumentation now make screening possible in academia. The history of the creation of such public or commercial collections and their accessibility is related. It shows that there is interest for an academic laboratory involved in medicinal chemistry, chemogenomics or "chemical biology" to organize its own collection and make it available through existing networks such as the French National chimiothèque or the European partner network "European Infrastructure of open screening platforms for Chemical Biology" EU-OpenScreen under construction.


  • Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4

    by Nancy Ty, Renée Pontikis, Guy G. Chabot, Emmanuelle Devillers, Lionel Quentin, Stéphane Bourg, Jean-Claude Florent


  • Azaindole derivatives are inhibitors of microtubule dynamics, with anti‐cancer and anti‐angiogenic activities

    by Renaud Prudent, Émilie Vassal‐Stermann, Chi‐Hung Nguyen, Marjorie Mollaret, Jean Viallet, Agnès Desroches‐Castan, Anne Martinez, Caroline Barette, Catherine Pillet, Glaucio Valdameri, et al.

    Background and Purpose: Drugs targeting microtubules are commonly used for cancer treatment. However, the potency of microtubule inhibitors used clinically is limited by the emergence of resistance. We thus designed a strategy to find new cell‐permeable microtubule‐targeting agents.Experimental Approach: Using a cell‐based assay designed to probe for microtubule polymerization status, we screened a chemical library and identified two azaindole derivatives, CM01 and CM02, as cell‐permeable microtubule‐depolymerizing agents. The mechanism of the anti‐tumour effects of these two compounds was further investigated both in vivo and in vitro.Key Results: CM01 and CM02 induced G2/M cell cycle arrest and exerted potent cytostatic effects on several cancer cell lines including multidrug‐resistant (MDR) cell lines. In vitro experiments revealed that the azaindole derivatives inhibited tubulin polymerization and competed with colchicines for this effect, strongly indicating that tubulin is the cellular target of these azaindole derivatives. In vivo experiments, using a chicken chorioallantoic xenograft tumour assay, established that these compounds exert a potent anti‐tumour effect. Furthermore, an assay probing the growth of vessels out of endothelial cell spheroids showed that CM01 and CM02 exert anti‐angiogenic activities.Conclusions and Implications: CM01 and CM02 are reversible microtubule‐depolymerizing agents that exert potent cytostatic effects on human cancer cells of diverse origins, including MDR cells. They were also shown to inhibit angiogenesis and tumour growth in chorioallantoic breast cancer xenografts. Hence, these azaindole derivatives are attractive candidates for further preclinical investigations.


  • Extensive characterization of sphere models established from colorectal cancer cell lines

    by Ada Collura, Laetitia Marisa, Diletta Trojan, Olivier Buhard, Anaïs Lagrange, Arnaud Saget, Marianne Bombled, Patricia Méchighel, Mira Ayadi, Martine Muleris, et al.

    Links between cancer and stem cells have been proposed for many years. As the cancer stem cell (CSC) theory became widely studied, new methods were developed to culture and expand cancer cells with conserved determinants of “stemness”. These cells show increased ability to grow in suspension as spheres in serum-free medium supplemented with growth factors and chemicals. The physiological relevance of this phenomenon in established cancer cell lines remains unclear. Cell lines have traditionally been used to explore tumor biology and serve as preclinical models for the screening of potential therapeutic agents. Here, we grew cell-forming spheres (CFS) from 25 established colorectal cancer cell lines. The molecular and cellular characteristics of CFS were compared to the bulk of tumor cells. CFS could be isolated from 72 % of the cell lines. Both CFS and their parental CRC cell lines were highly tumorigenic. Compared to their parental cells, they showed similar expression of putative CSC markers. The ability of CRC cells to grow as CFS was greatly enhanced by prior treatment with 5-fluorouracil. At the molecular level, CFS and parental CRC cells showed identical gene mutations and very similar genomic profiles, although microarray analysis revealed changes in CFS gene expression that were independent of DNA copy-number. We identified a CFS gene expression signature common to CFS from all CRC cell lines, which was predictive of disease relapse in CRC patients. In conclusion, CFS models derived from CRC cell lines possess interesting phenotypic features that may have clinical relevance for drug resistance and disease relapse.


  • Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic Growth

    by Renaud Prudent, Emilie Vassal-Stermann, Chi-Hung Nguyen, Catherine Pillet, Anne Martinez, Chloé Prunier, Caroline Barette, Emmanuelle Soleilhac, Odile Filhol, Anne Beghin, et al.

    The emergence of tumor resistance to conventional microtubule-targeting drugs restricts their clinical use. Using a cell-based assay that recognizes microtubule polymerization status to screen for chemicals that interact with regulators of microtubule dynamics, we identified Pyr1, a cell permeable inhibitor of LIM kinase, which is the enzyme that phosphorylates and inactivates the actin-depolymerizing factor cofilin. Pyr1 reversibly stabilized microtubules, blocked actin microfilament dynamics, inhibited cell motility in vitro and showed anticancer properties in vivo, in the absence of major side effects. Pyr1 inhibition of LIM kinase caused a microtubule-stabilizing effect, which was independent of any direct effects on the actin cytoskeleton. In addition, Pyr1 retained its activity in multidrug-resistant cancer cells that were resistant to conventional microtubule-targeting agents. Our findings suggest that LIM kinase functions as a signaling node that controls both actin and microtubule dynamics. LIM kinase may therefore represent a targetable enzyme for cancer treatment. Cancer Res; 72(17); 4429–39. ©2012 AACR.


  • SNAP‐tag Based Proteomics Approach for the Study of the Retrograde Route

    by Getao Shi, Michel Azoulay, Florent Dingli, Christophe Lamaze, Damarys Loew, Jean‐Claude Florent, Ludger Johannes

    Proteomics is a powerful technique for protein identification at large scales. A number of proteomics approaches have been developed to study the steady state composition of intracellular compartments. Here, we report a novel vectorial proteomics strategy to identify plasma membrane proteins that undergo retrograde transport to the trans-Golgi network (TGN). This strategy is based on the covalent modification of the plasma membrane proteome with a membrane impermeable benzylguanine derivative. Benzylguanine-tagged plasma membrane proteins that are subsequently targeted to the retrograde route are covalently captured by a TGN-localized SNAP-tagged fusion protein, which allows for their identification. The approach was validated step-by-step using a well explored retrograde cargo protein, the B-subunit of Shiga toxin. It was then extended to the proteomics format. Among other hits we found one of the historically first identified cargo proteins that undergo retrograde transport, which further validated our approach. Most of the other hits were kinases, receptors or transporters. In conclusion, we have pioneered a vectorial proteomics approach that complements traditional methods for the study of retrograde protein trafficking. This approach is of generic nature and could in principle be extended to other endocytic pathways.